Hemay 020

Drug Profile

Hemay 020

Alternative Names: Hemay020

Latest Information Update: 08 Oct 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hainan General Sanyang Pharmaceutical; Tianjin Hemay Biotech
  • Class Antineoplastics
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 01 Aug 2015 Phase-I clinical trials in Non-small cell lung cancer (Late-stage disease) in China (PO)
  • 01 Aug 2015 Phase-I clinical trials in Solid tumours (Late-stage disease) in China (PO)
  • 19 Jun 2015 Tianjin Hemay Pharmaceutical and Hainan General Sanyang Pharmaceutical plan a phase I trial for Solid tumours and Non small cell lung cancer in China (NCT02467569)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top